Small molecule · Inhibitor of phosphatidylinositol-3-kinase alpha (PI3Kα) (PIK3CA) · developed by Novartis
Alpelisib is an oral inhibitor of phosphatidylinositol-3-kinase, acting predominantly on the PI3Kα isoform encoded by PIK3CA, and thereby suppressing Akt signaling in cells with PIK3CA mutations. It is studied in PIK3CA-related Overgrowth Spectrum (PROS) and is used with fulvestrant in PIK3CA-mutated breast cancer.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 15, 2025). Read the full label for the exact wording, limitations and safety information.
PIK3CA-related Overgrowth Spectrum (PROS)
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →